Handelsbanken Fonder
FATE icon

Handelsbanken Fonder’s Fate Therapeutics FATE Stock Holding History

Handelsbanken Fonder’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,300
Closed -$298K – 1575
2022
Q3 		$298K Hold
13,300
– – ﹤0.01% 1254
2022
Q2 		$330K Hold
13,300
– – ﹤0.01% 1275
2022
Q1 		$516K Sell
13,300
-1,900
-13% -$73.6K ﹤0.01% 1182
2021
Q4 		$889K Hold
15,200
– – ﹤0.01% 957
2021
Q3 		$901K Hold
15,200
– – ﹤0.01% 960
2021
Q2 		$1.32M Buy
15,200
+1,800
+13% +$145K 0.01% 780
2021
Q1 		$1.1M Hold
13,400
– – 0.01% 793
2020
Q4 		$1.22M Hold
13,400
– – 0.01% 746
2020
Q3 		$536K Buy
13,400
+2,900
+28% +$101K ﹤0.01% 960
2020
Q2 		$360K Buy
+10,500
New +$313K ﹤0.01% 1121

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Handelsbanken Fonder's FATE Position: Q4 2022 in Review

Handelsbanken Fonder sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 13,300 shares — an estimated $298K sold.

Handelsbanken Fonder first reported a position in FATE in Q2 2020 and held it in 10 quarters. The position peaked at $1.32M in Q2 2021. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • Handelsbanken Fonder reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Handelsbanken Fonder sold 13,300 Fate Therapeutics shares in Q4 2022, an estimated $298K.
  • Handelsbanken Fonder first reported a position in Fate Therapeutics in Q2 2020 and held it in 10 quarters.
  • Handelsbanken Fonder's Fate Therapeutics position peaked at $1.32M in Q2 2021.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on Handelsbanken Fonder's 13F filing for Q4 2022, filed 7 Feb 2023.